Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Macromol Biosci. 2016 Jul 1;17(1):10.1002/mabi.201600194. doi: 10.1002/mabi.201600194

Table 3.

Expression of AKT and pAKT in treatment group (positive/total cases). Mod=moderate.

Study group AKT pAKT
Vehicle 8/8, diffuse mod 7/8, weak(5), mod(2)
PTX 4/4 diffuse, mod 0/4
P/17 4/4 diffuse, weak 4/4 focal weak(3), mod(1)
P/R 4/4 diffuse weak(3), mod(1) 4/4 focal weak(3), mod(1)
17/R 4/4 diffuse weak(3), mod(1) 0/4
Low TRIO 4/4 diffuse, mod 3/4 focal mod(1), weak(2)
Int. TRIO 4/4 diffuse, mod 4/4 focal mod(3), weak(1)
High TRIO 4/4 diffuse, mod 2/4 focal mod(1), weak(1)
TRIO day 6 4/4 diffuse, mod 3/4 focal mod
Vehicle + XRT 4/4 diffuse mod(2), strong(2) 2/4 focal mod
TRIO + XRT 4/4 diffuse, mod 3/4 focal mod(2), weak(1)
HHS Vulnerability Disclosure